BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 33419453)

  • 1. Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative.
    Zettergren A; Lord J; Ashton NJ; Benedet AL; Karikari TK; Lantero Rodriguez J; ; Snellman A; Suárez-Calvet M; Proitsi P; Zetterberg H; Blennow K
    Alzheimers Res Ther; 2021 Jan; 13(1):17. PubMed ID: 33419453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-Amyloid-Dependent and -Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease.
    Kumar A; Janelidze S; Stomrud E; Palmqvist S; Hansson O; Mattsson-Carlgren N;
    Neurology; 2022 Aug; 99(5):e476-e487. PubMed ID: 35641311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.
    Karikari TK; Benedet AL; Ashton NJ; Lantero Rodriguez J; Snellman A; Suárez-Calvet M; Saha-Chaudhuri P; Lussier F; Kvartsberg H; Rial AM; Pascoal TA; Andreasson U; Schöll M; Weiner MW; Rosa-Neto P; Trojanowski JQ; Shaw LM; Blennow K; Zetterberg H;
    Mol Psychiatry; 2021 Feb; 26(2):429-442. PubMed ID: 33106600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer's disease.
    Chen SD; Huang YY; Shen XN; Guo Y; Tan L; Dong Q; Yu JT;
    Transl Psychiatry; 2021 Jun; 11(1):356. PubMed ID: 34120152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline.
    Ni M; Zhu ZH; Gao F; Dai LB; Lv XY; Wang Q; Zhu XX; Xie JK; Shen Y; Wang SC; Xie Q;
    ACS Chem Neurosci; 2023 Jan; 14(1):170-179. PubMed ID: 36547971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults.
    McGrath ER; Beiser AS; O'Donnell A; Yang Q; Ghosh S; Gonzales MM; Himali JJ; Satizabal CL; Johnson KA; Tracy RP; Seshadri S
    J Alzheimers Dis; 2022; 87(4):1517-1526. PubMed ID: 35491781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease.
    Wilson EN; Young CB; Ramos Benitez J; Swarovski MS; Feinstein I; Vandijck M; Le Guen Y; Kasireddy NM; Shahid M; Corso NK; Wang Q; Kennedy G; Trelle AN; Lind B; Channappa D; Belnap M; Ramirez V; Skylar-Scott I; Younes K; Yutsis MV; Le Bastard N; Quinn JF; van Dyck CH; Nairn A; Fredericks CA; Tian L; Kerchner GA; Montine TJ; Sha SJ; Davidzon G; Henderson VW; Longo FM; Greicius MD; Wagner AD; Wyss-Coray T; Poston KL; Mormino EC; Andreasson KI
    Alzheimers Res Ther; 2022 Nov; 14(1):172. PubMed ID: 36371232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
    Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
    ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma p-tau181 Level Predicts Neurodegeneration and Progression to Alzheimer's Dementia: A Longitudinal Study.
    Wang YL; Chen J; Du ZL; Weng H; Zhang Y; Li R; Jia Z; Sun M; Jiang J; Wang FZ; Xu J;
    Front Neurol; 2021; 12():695696. PubMed ID: 34557143
    [No Abstract]   [Full Text] [Related]  

  • 12. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
    Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer's Disease Continuum.
    Chen YH; Lin RR; Huang HF; Xue YY; Tao QQ
    Front Aging Neurosci; 2022; 14():848180. PubMed ID: 35847667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal Fluid Alzheimer's Disease Biomarker Patterns of Change Prior to the Onset of Mild Cognitive Impairment.
    Sun Y; Moghekar A; Soldan A; Pettigrew C; Greenberg B; Albert M; Wang MC;
    J Alzheimers Dis; 2023; 96(1):287-300. PubMed ID: 37742656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease.
    Darst BF; Koscik RL; Racine AM; Oh JM; Krause RA; Carlsson CM; Zetterberg H; Blennow K; Christian BT; Bendlin BB; Okonkwo OC; Hogan KJ; Hermann BP; Sager MA; Asthana S; Johnson SC; Engelman CD
    J Alzheimers Dis; 2017; 55(2):473-484. PubMed ID: 27662287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
    JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Non-APOE Polygenic Risk Score for Alzheimer's Disease Is Associated With Cerebrospinal Fluid Neurofilament Light in a Representative Sample of Cognitively Unimpaired 70-Year Olds.
    Skoog I; Kern S; Najar J; Guerreiro R; Bras J; Waern M; Zetterberg H; Blennow K; Zettergren A
    J Gerontol A Biol Sci Med Sci; 2021 May; 76(6):983-990. PubMed ID: 33512503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer's disease pathology.
    Silva-Spínola A; Leitão MJ; Nadal A; Le Bastard N; Santana I; Baldeiras I
    Alzheimers Res Ther; 2024 Mar; 16(1):51. PubMed ID: 38454502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition.
    Tideman P; Stomrud E; Leuzy A; Mattsson-Carlgren N; Palmqvist S; Hansson O;
    Neurology; 2022 Apr; 98(15):e1525-e1533. PubMed ID: 35022305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex differences in plasma p-tau181 associations with Alzheimer's disease biomarkers, cognitive decline, and clinical progression.
    Tsiknia AA; Edland SD; Sundermann EE; Reas ET; Brewer JB; Galasko D; Banks SJ;
    Mol Psychiatry; 2022 Oct; 27(10):4314-4322. PubMed ID: 35768637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.